Rapport Therapeutics reported Monday that RAP-219 hit its primary endpoint in a Phase 2 trial for bipolar mania, with patients on the drug showing a 15.4-point drop from baseline on the Young Mania Rating Scale compared to 12.3 points in the placebo group. That 3.1-point placebo-adjusted difference at Week 3 cleared statistical significance (p=0.045), and the company says key secondary endpoints also held. For a field where approved options, from lithium to atypical antipsychotics like aripiprazole, carry weight-gain, sedation, and metabolic liabilities that drive discontinuation, a mechanistically distinct drug showing clean Phase 2 signal draws attention on its own terms.
What makes RAP-219’s mechanism worth tracking is its selectivity. Rather than blocking dopamine or serotonin receptors broadly, it acts as a negative allosteric modulator of AMPA receptors specifically through TARPγ8, a transmembrane protein concentrated in the hippocampus, amygdala, and cortex. That anatomical specificity is what Rapport is betting will separate the compound’s tolerability profile from older psychiatric drugs, though the Phase 2 data set is not large enough yet to draw firm conclusions on that front.
The trial’s design and full dataset have not been disclosed in the 8-K itself, which simply furnishes the press release as an exhibit under Regulation FD. How many patients were enrolled, the duration beyond Week 3, dropout rates, and any emergent adverse events all remain to be detailed at the conference call and webcast Rapport hosted on October 20. A 3.1-point YMRS separation is statistically significant, but the clinical meaningfulness of that magnitude is a question the broader data package will need to answer before Phase 3 planning looks straightforward.
The number that will define RAP-219’s next chapter is whatever sample size and YMRS threshold Rapport chooses for a pivotal trial. A Phase 2 effect size this modest demands a powered, well-stratified Phase 3 to confirm it, and the 3.1-point separation at Week 3 sets an honest but demanding bar for replication.
Source link: https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134d8k.htm
RAP-219: the facts in one place
- Also written: JNJ-64300912
- Sponsor: Rapport Therapeutics
- Mechanism: negative allosteric modulator of TARPγ8, selectively inhibiting TARPγ8-containing AMPA receptors
- Indication studied: acute bipolar mania in adults with bipolar I disorder; focal onset seizures; neuropathic pain
- Phase: Phase 2 (bipolar mania); Phase 3 (focal onset seizures); Phase 1 (neuropathic pain)
- Enrollment: 253
- Primary endpoint: placebo-adjusted change in Young Mania Rating Scale (YMRS) total score at Week 3
- Headline result: statistically significant 3.1-point placebo-adjusted improvement in YMRS total score at Week 3; RAP-219-treated patients achieved a 15.4-point mean reduction from baseline
- Registry identifier: NCT07046494
- Current status: Phase 2 complete for acute bipolar mania with positive topline results; FDA meeting planned Q1 2027 to discuss registrational trial design; two Phase 3 trials for acute bipolar mania expected to initiate second half of 2027
- positive topline Phase 2 results announced: October 20, 2026
- FDA meeting to discuss registrational trial design: Q1 2027
- Phase 3 trial initiation (acute bipolar mania): second half of 2027
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
